A pooled analysis of phase II trials investigating a PD1 or PD-L1 antagonist in patients with advanced STS, the ORR of PD-1/PD-L1 antibody as single-agent immunotherapy was 15.8% (22). This evidence concerns the gene CD274 and telomere syndrome.